Erectile dysfunction and Female sexuality

Viagra for women has few advantages

Flibanserin, the pleasure pill for the woman, caused a stir recently. A study has now examined the benefits. The result is far from satisfactory

Flibanserin is supposed to promote a sense of pleasure in women

In August, the US authorities approved a drug containing flibanserin. In Germany, too, the so-called Lustpille for women made for controversial discussions. Some commented on a breakthrough in sex therapy comparable to Viagra in men in the 1990s. Others warned that the drug could put more pressure on women.

Little pleasure, significant disadvantages

A lot of noise about nothing? The journal JAMA published an analysis in which researchers took a closer look at the benefits of flibanserin. On average, women taking the pleasure-enhancing drug had a fulfilling sexual experience just once every two months more than those receiving a placebo. For the study, the scientists evaluated the data from eight different studies, which included a total of 5914 participants.

This meager pleasure gain was countered by numerous unwanted side effects. Women complained under the influence of pink pills aggravated by complaints such as dizziness and nausea.

The data in the studies was thin, the authors write. Therefore, they advise caution in interpreting their results. At the same time, in view of the low benefit and the significant disadvantages, they are in favor of further investigations before flibanserin finds its way into the treatment guidelines of physicians.

Effect on hormone balance

Flibanserin is colloquially usually referred to as “Viagra for the woman”. Strictly speaking, this expression is not correct. Because Viagra helps men who want, but whose body does not play along as desired. Flibanserin, on the other hand, is intended to increase sexual desire by influencing the release of messenger substances in the brain, such as dopamine and serotonin.

Critics complain that the device would brand female displeasure as an illness. In addition, it probably only has an effect on a small proportion of women. Whether and when flibanserin is launched in Germany is still unclear.